irinotecan has been researched along with Rhabdomyosarcoma in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.09) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 13 (29.55) | 24.3611 |
| 2020's | 10 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Aladowicz, E; Bernauer, C; Box, G; Clarke, M; de Haven-Brandon, A; Galiwango, D; Gatz, SA; Generali, M; Gonzalez De Castro, D; Hayes, A; Izquierdo, E; Kelsey, A; Kirkin, V; Man, SYK; Milton, CI; Missiaglia, E; Raynaud, FI; Selfe, J; Shipley, JM; Valenti, M; Walters, ZS | 1 |
| B, H; Canute Fernandes, S; Rastogi, S | 1 |
| Bisogno, G; Bogart, E; Calareso, G; Casanova, M; Chisholm, JC; Defachelles, AS; Gatz, SA; Le Deley, MC; McHugh, K; Melcon, SG; Merks, JHM; Minard-Colin, V; Probst, A; Rocourt, N; van Rijn, RR | 1 |
| Huang, H; Li, W; Qu, S; Yao, Y | 1 |
| Cole, KA; Fox, E; Ijaz, H; Liu, X; Maris, JM; Minard, CG; Reid, JM; Santi, M; Surrey, LF; Voss, S; Weigel, BJ | 1 |
| Bautista, F; Brennan, BJ; Campbell-Hewson, Q; Cañete Nieto, A; Casanova, M; Chung, JW; Corradini, N; Geoerger, B; Makin, G; Marshall, LV; Mueller, U; Ploeger, BA; Verschuur, AC; Zebger-Gong, H | 1 |
| Hara, J; Hosoi, H; Hosono, A; Kikuta, A; Koh, K; Miyachi, M; Ogawa, A; Teramukai, S; Tsuchiya, K | 1 |
| Bandyopadhyay, A; Chen, Y; Erickson, SW; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; Lai, Z; Phelps, DA; Robles, AJ; Smith, MA | 1 |
| Hirai, M; Ito, M; Kaneda, H; Morioka, I; Oba, D; Yagasaki, H | 1 |
| Earley, E; Erickson, SW; Houghton, PJ; Kurmasheva, RT; Smith, MA | 1 |
| Balaguer-Lluna, L; Baulenas-Farres, M; Burgueño, V; Carcaboso, AM; Carrasco, R; Castañeda, A; Castillo-Ecija, H; Celis, V; Cruz, O; Cuadrado-Vilanova, M; Garraus, M; Gorostegui, M; Jimenez-Cabaco, A; Krauel, L; Lavarino, C; Manzanares, A; Monterrubio, C; Mora, J; Morales La Madrid, A; Muñoz-Aznar, O; Olaciregui, NG; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Salvador, N; Santa-Maria, V; Suñol, M; Torner, F; Vancells, M; Vicario, FJ; Vila-Ubach, M | 1 |
| Bahrami, A; Blankenship, K; Bradley, C; Chen, X; Clay, MR; Dapper, J; Downing, J; Dyer, MA; Easton, J; Federico, SM; Freeman, BB; Gordon, B; Honnell, V; Karlstrom, A; Mardis, ER; Ocarz, M; Pappo, A; Shelat, AA; Stewart, E; Twarog, NR; Wilson, RK; Wu, J; Xu, B; Zhang, J; Zhou, X | 1 |
| Botteri, G; Cano, F; Carcaboso, AM; Castillo-Ecija, H; Garcia-Alvarez, L; Manzanares, A; Monterrubio, C; Mora, J; Pascual-Pasto, G; Restrepo-Perdomo, CA; Ruiz, B; Sosnik, A; Suñol, M; Tornero, JA; Vazquez-Carrera, M | 1 |
| Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B | 1 |
| Arndt, CA; Casey, DL; Chi, YY; Donaldson, SS; Gupta, AA; Hawkins, DS; Lautz, TB; Rodeberg, DA; Routh, JC; Tian, J; Wolden, SL; Yock, TI | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Deng, D; Fang, HB; Tan, M; Zhang, T | 1 |
| Anderson, JR; Arndt, CA; Hawkins, DS; Lyden, E; Meyer, WH; Michalski, JM; Parham, DM; Rodeberg, DA; Weigel, BJ | 1 |
| Baumgart, JT; Edessa, LD; Helman, LJ; Heske, CM; Lee, S; Mendoza, A; Neckers, L; Proia, DA; Trepel, J | 1 |
| Cusano, G; D'Incalci, M; Di Francesco, AM; Forestieri, D; Meco, D; Patriarca, V; Pisano, C; Riccardi, R; Servidei, T; Zucchetti, M | 1 |
| Anderson, JR; Breitfeld, PP; Donaldson, SS; Hawkins, DS; Lyden, ER; Mascarenhas, L; Meyer, WH; Paidas, CN; Parham, DM; Walterhouse, DO | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Dharmarajan, KV; Wexler, LH; Wolden, SL | 1 |
| Ahmed, B; De Boeck, G; de Bruijn, EA; Guetens, G; Landuyt, W; van Oosterom, AT; Wildiers, H | 1 |
| Liang, H; Sha, N | 1 |
| Fang, HB; Houghton, PJ; Tan, M; Tian, GL | 1 |
| Cheshire, PJ; Danks, MK; Houghton, PJ; Hyatt, JL; Iacono, L; Morton, CL; Potter, PM; Stewart, CF; Taylor, KR | 1 |
| Morikawa, Y | 1 |
| D'Incalci, M; Faircloth, GT; Jimeno, J; Marabese, M; Mazzarella, G; Meco, D; Riccardi, A; Riccardi, R; Ubezio, P | 1 |
| Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M | 1 |
| Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
| Gupta, AA; Pappo, AS | 1 |
| Assadourian, S; Bergeron, C; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Morland, B; Orbach, D; Pichon, F; Picton, S; Stockdale, E; Vassal, G | 1 |
| Breitfeld, P; Crews, KR; Donaldson, SS; Houghton, P; Lyden, E; Meyer, WH; Pappo, AS; Parham, D; Wiener, E | 1 |
| Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
| Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A | 1 |
| Danks, MK; Morton, CL; Pawlik, CA; Potter, PM | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| Danks, MK; Guichard, SM; Harris, LC; Iyengar, RV; Khanna, R; Krull, EJ; Mason, SE; Pawlik, CA; Potter, PM | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Burger, RA; Danks, MK; Harris, LC; Iyengar, RV; Krull, EJ; Pawlik, CA; Phelps, DA; Potter, PM | 1 |
| Danks, MK; Harris, LC; Morton, CL; Potter, PM; Weeks, JK; Wierdl, M | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Houghton, PJ; Santana, VM | 1 |
4 review(s) available for irinotecan and Rhabdomyosarcoma
| Article | Year |
|---|---|
[Childhood rhabdomyosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Humans; Irinotecan; Radiotherapy Dosage; Rhabdomyosarcoma; Risk; Vincristine | 2005 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2006 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
10 trial(s) available for irinotecan and Rhabdomyosarcoma
| Article | Year |
|---|---|
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cerebellar Neoplasms; Child; Humans; Irinotecan; Medulloblastoma; Neuroblastoma; Protein-Tyrosine Kinases; Rhabdomyosarcoma | 2023 |
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma, Ewing; Therapies, Investigational; Vincristine | 2023 |
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Dactinomycin; Humans; Irinotecan; Neoplasm Staging; Rhabdomyosarcoma; Treatment Outcome; Vincristine | 2019 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vincristine | 2016 |
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Recurrence; Rhabdomyosarcoma; Risk Factors; Time Factors; Treatment Outcome; United States; Vincristine | 2010 |
Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Child; Female; Humans; Irinotecan; Male; Pilot Projects; Rhabdomyosarcoma; Soft Tissue Neoplasms | 2013 |
Irinotecan for children with relapsed solid tumors.
Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor | 2006 |
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Rhabdomyosarcoma; Survival Analysis; Treatment Outcome | 2007 |
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Metastasis; Rhabdomyosarcoma; Treatment Outcome; Vincristine | 2007 |
30 other study(ies) available for irinotecan and Rhabdomyosarcoma
| Article | Year |
|---|---|
FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Topics: Autocrine Communication; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Fibroblast Growth Factor 7; Humans; Irinotecan; Protein Kinase Inhibitors; Receptor, Fibroblast Growth Factor, Type 2; Rhabdomyosarcoma | 2022 |
VIT-0910: Need for Cautious Optimism?
Topics: Adult; Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Temozolomide; Therapies, Investigational; Vincristine | 2022 |
Reply to H. B et al.
Topics: Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Temozolomide; Therapies, Investigational; Vincristine | 2022 |
An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report.
Topics: Adult; Child; Humans; Ifosfamide; Irinotecan; Male; Perineum; Rhabdomyosarcoma; Rhabdomyosarcoma, Embryonal; Young Adult | 2022 |
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Ketones; Kidney Neoplasms; Mice; Mice, SCID; Prognosis; Rhabdomyosarcoma; Tumor Cells, Cultured; Vincristine; Wilms Tumor; Xenograft Model Antitumor Assays | 2020 |
Successful treatment of stage 4 rhabdomyosarcoma in a female with Williams-Beuren syndrome.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Irinotecan; Neoplasm Staging; Proton Therapy; Rhabdomyosarcoma; Vincristine; Williams Syndrome | 2020 |
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Topics: Animals; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cyclophosphamide; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Irinotecan; Mice; Mice, SCID; Morpholines; Pyridones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2021 |
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Topics: Adolescent; Animals; Child; Child, Preschool; Disease Models, Animal; Female; Heterografts; Humans; Irinotecan; Male; Mice; Osteosarcoma; Prognosis; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Orthotopic patient-derived xenografts of paediatric solid tumours.
Topics: Animals; Bortezomib; Camptothecin; Cell Cycle Proteins; Child; Clone Cells; Drug Therapy, Combination; Epigenesis, Genetic; Female; Heterografts; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Indoles; Irinotecan; Mice; Neoplasms; Nuclear Proteins; Panobinostat; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Tissue Compatibility of SN-38-Loaded Anticancer Nanofiber Matrices.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Hepatocytes; Humans; Irinotecan; Kidney; Liver; Mice; Nanofibers; Rats, Wistar; Rhabdomyosarcoma | 2018 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neuroblastoma; Osteosarcoma; Remission Induction; Retreatment; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Temozolomide; Vincristine; Wilms Tumor | 2019 |
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Extremities; Female; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Irinotecan; Male; Radiotherapy; Randomized Controlled Trials as Topic; Retroperitoneal Neoplasms; Rhabdomyosarcoma; Risk; Treatment Failure; Urinary Bladder Neoplasms; Vincristine; Young Adult | 2019 |
Modeling sustained treatment effects in tumor xenograft experiments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Interactions; Humans; Irinotecan; Mice; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Resorcinols; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Rhabdomyosarcoma; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Drug Interactions; Drug Synergism; Humans; Irinotecan; Neoplasm Transplantation; Rats; Rhabdomyosarcoma; Stilbenes; Time Factors; Tumor Cells, Cultured | 2004 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Likelihood Functions; Longitudinal Studies; Mice; Mice, SCID; Models, Biological; Models, Statistical; Neoplasms, Experimental; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2005 |
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Dose-Response Relationship, Drug; Esterases; Gastrointestinal Tract; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Transplantation; Rhabdomyosarcoma; Sarcoma, Experimental | 2005 |
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dioxoles; DNA Topoisomerases, Type I; Humans; In Vitro Techniques; Irinotecan; Isoquinolines; Male; Mice; Mice, Nude; Rhabdomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1993 |
Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Cell Division; Drug Screening Assays, Antitumor; Humans; Irinotecan; Liver; Prodrugs; Rabbits; Rhabdomyosarcoma; Tumor Cells, Cultured | 1998 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Topics: Animals; Blotting, Northern; Blotting, Southern; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Genetic Vectors; Humans; Irinotecan; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Tumor Cells, Cultured | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Glioblastoma; Humans; Immunoblotting; Irinotecan; MyoD Protein; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Transgenes; Tumor Cells, Cultured | 2001 |
Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; DNA, Complementary; Drug Screening Assays, Antitumor; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Liver; Rabbits; Rhabdomyosarcoma; Transduction, Genetic; Tumor Cells, Cultured | 2001 |
Clinical trials using irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2002 |